AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024

Goldman Sachs Reiterates Conviction Buy Rating on Amgen (AMGN)

October 16, 2024 6:02 AM EDT

Goldman Sachs analyst Salveen Richter reiterated a Conviction Buy rating and $369.00 price target on Amgen (NASDAQ: AMGN).

The analyst comments "While AMGN continues to execute through a catalyst-rich year, the focus remains on key upcoming Ph2 obesity data for MariTide (GLP1-R agonistAn agonist is a drug that binds to a receptor and amplifies its intended effect./GIPR antagonist), expected by YE24, where positive results could unlock access to the obesity mega-TAM... More